Business Wire

Artificial Intelligence Fuels Rise of Hard-to-Detect Bots That Now Make up More Than Half of Global Internet Traffic, According to the 2025 Imperva Bad Bot Report

Share

Thales, the leading global technology and security provider, today announced the release of the 2025 Imperva Bad Bot Report, a global analysis of automated bot traffic across the internet. This year’s report, the 12th annual research study, reveals that generative artificial intelligence (AI) is revolutionizing the development of bots, allowing less sophisticated actors to launch a higher volume of bot attacks with increased frequency. Today’s attackers are also leveraging AI to scrutinize their unsuccessful attempts and refine techniques to evade security measures with heightened efficiency, amidst a growing Bots-As-A-Service (BaaS) ecosystem of commercialized bot services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415432215/en/

©Thales

Automated bot traffic surpassed human-generated traffic for the first time in a decade, constituting 51% of all web traffic in 2024. This shift is largely attributed to the rise of AI and Large Language Models (LLMs), which have simplified the creation and scaling of bots for malicious purposes. As AI tools become more accessible, cyber criminals are increasingly leveraging these technologies to create and deploy malicious bots which now account for 37% of all internet traffic – a significant increase from 32% in 2023. This is the sixth consecutive year of growth in bad bot activity, posing security challenges for organizations striving to safeguard their digital assets.

Both the Travel and the Retail sectors face an advanced bot problem, with bad bots making up 41% and 59% of their traffic respectively. In 2024, the travel industry became the most attacked sector, accounting for 27% of all bot attacks, up from 21% in 2023. The most notable shift in 2024 is the decline in advanced bot attacks targeting the travel industry (41%, down from 61% in 2023) and the sharp increase in simple bot attacks (52%, up from 34%). This shift indicates that AI-powered automation tools have lowered the barriers to entry for attackers, allowing less sophisticated actors to initiate more basic bot attacks. Rather than relying exclusively on sophisticated techniques, cybercriminals are increasingly utilizing high volumes of simpler bots to inundate travel sites, resulting in more frequent and widespread attacks.

The Rise of AI-Driven Bots: A New Era of Cybersecurity Challenges

The emergence of advanced AI tools, including ChatGPT, ByteSpider Bot, ClaudeBot, Google Gemini, Perplexity AI, and Cohere AI, are transforming not just user interactions but also the methods by which attackers execute cyber threats.According to the Imperva Threat Research team, widely used AI tools are being leveraged for cyberattacks, with ByteSpider Bot alone responsible for 54% of all AI-enabled attacks. Other significant contributors include AppleBot at 26%, ClaudeBot at 13%, and ChatGPT User Bot at 6%.

“The surge in AI-driven bot creation has serious implications for businesses worldwide,” said Tim Chang, General Manager of Application Security at Thales. “As automated traffic accounts for more than half of all web activity, organizations face heightened risks from bad bots, which are becoming more prolific every day.”

As attackers become more adept at utilizing AI, they can execute a variety of cyber threats—ranging from DDoS attacks to custom rules exploitation and API violations. While bot-driven attacks have become increasingly sophisticated, they pose significant challenges for detection efforts.

“This year’s report sheds light on the evolving tactics and techniques utilized by bot attackers. What were once deemed advanced evasion methods have now become standard practice for many malicious bots,” Chang said. “In this rapidly changing environment, businesses must evolve their strategies. It's crucial to adopt an adaptive and proactive approach, leveraging sophisticated bot detection tools and comprehensive cybersecurity management solutions to build a resilient defense against the ever-shifting landscape of bot-related threats.”

Bad Bots Targeting API Business Logic Pose Increased Threat to Modern Enterprises

Recent findings from the Imperva Threat Research team reveal a significant surge in API-directed attacks, with 44% of advanced bot traffic targeting APIs. These attacks aren't just limited to overwhelming API endpoints; rather, they target the intricate business logic that defines how APIs operate. Attackers deploy bots specifically designed to exploit vulnerabilities in API workflows, engaging in automated payment fraud, account hijacking, and data exfiltration.

Analysis in the report reveals a deliberate strategy by cyber attackers to exploit API endpoints that manage sensitive and high-value data. Implications of this trend are especially impactful for industries that rely on APIs for their critical operations and transactions. Financial services, healthcare, and e-commerce sectors are bearing the brunt of these sophisticated bot attacks, making them prime targets for malicious actors seeking to breach sensitive information.

APIs serve as the backbone of modern applications, enabling connectivity across services, streamlining operations, and delivering personalized customer experiences at scale. They underpin essential functions such as payment processing, supply chain management, and AI-driven analytics, making them indispensable for enhancing efficiency, accelerating product development, and unlocking new revenue streams.

“The business logic inherent to APIs is powerful, but it also creates unique vulnerabilities that malicious actors are eager to exploit,” Chang said. “As organizations embrace cloud-based services and microservices architectures, it’s vital to understand that the very features that make APIs essential can also leave them susceptible to risk of fraud and data breaches.”

Financial Services, Healthcare, and E-commerce Industries Face Heightened Risk

The 2025 Imperva Bad Bot Report provides an in-depth analysis highlighting the industries most at risk. Financial services, healthcare, and e-commerce are the most affected sectors, industries that rely on APIs for critical operations and sensitive transactions, making them attractive targets for sophisticated bot attacks.

The financial services sector was the most targeted industry for account takeover (ATO) attacks, accounting for 22% of all incidents, followed by Telecoms and ISPs with 18%, and Computing & IT with 17%. Financial Services has long been a prime target for ATO attacks due to the high value of accounts and the sensitive nature of the data at stake. Banks, credit card companies, and fintech platforms possess vast amounts of Personally Identifiable Information (PII), including credit card and bank account details, which can be profitably sold on the dark web. Additionally, the growing proliferation of APIs within the industry has broadened the attack surface, allowing cyber criminals to exploit vulnerabilities such as weak authentication and authorization methods, thereby facilitating account takeovers and data theft.

About the Research

The 12th Annual Imperva Bad Bot Report is based on insights from our Threat Research and Security Analyst Services (SAS) teams. Our analysis draws from data collected from across the Imperva global network in 2024, including the blocking of 13 trillion bad bot requests across thousands of domains and industries. This dataset provides key insights into bot activity to help organizations understand and address the growing risks of automated attacks.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

PLEASE VISIT
Thales Group
Cybersecurity Products
Cybersecurity Solutions

View source version on businesswire.com: https://www.businesswire.com/news/home/20250415432215/en/

Contacts

PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye